$RXRX has been mentioned 31 times over the past 12 months by 6 distinct FinTwit voices, with the first mention appearing on November 5, 2025. @investmentguru_ dominates discussion of the stock with 23 mentions, followed by @midascabal with 3 mentions and @alphaticaio, @adamfeuerstein, and @the_ai_investor each with 1 mention. The most recent activity occurred on July 2, 2026, with long research content representing the primary category of discussion around this ticker.

Recursion Pharmaceuticals appears in the broader biotechnology sector conversation, where it is positioned alongside other companies leveraging AI and automation technologies. The stock has been referenced in curated biotechnology sector watchlists and discussions about capital rotation toward biotech opportunities, with @investmentguru_ framing it as part of a convergence between genetics, artificial intelligence, and precision therapies in modern medicine.